Y-MABS THERAPEUTICS INC (YMAB) Stock Price & Overview
NASDAQ:YMAB • US9842411095
The current stock price of YMAB is 8.61 USD. Today YMAB is up by 0.23%. In the past month the price increased by 1.06%. In the past year, price decreased by -37.29%.
YMAB Key Statistics
- Market Cap
- 391.238M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.50
- Dividend Yield
- N/A
YMAB Stock Performance
YMAB Stock Chart
YMAB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to YMAB. When comparing the yearly performance of all stocks, YMAB is one of the better performing stocks in the market, outperforming 85.61% of all stocks.
YMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to YMAB. No worries on liquidiy or solvency for YMAB as it has an excellent financial health rating, but there are worries on the profitability.
YMAB Earnings
On August 8, 2025 YMAB reported an EPS of -0.07 and a revenue of 19.52M. The company beat EPS expectations (74.16% surprise) and beat revenue expectations (4.07% surprise).
YMAB Forecast & Estimates
16 analysts have analysed YMAB and the average price target is 8.2 USD. This implies a price decrease of -4.75% is expected in the next year compared to the current price of 8.61.
For the next year, analysts expect an EPS growth of -24.97% and a revenue growth -5.98% for YMAB
YMAB Groups
Sector & Classification
YMAB Financial Highlights
Over the last trailing twelve months YMAB reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 10.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.96% | ||
| ROE | -25.4% | ||
| Debt/Equity | 0 |
YMAB Ownership
YMAB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About YMAB
Company Profile
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Company Info
IPO: 2018-09-21
Y-MABS THERAPEUTICS INC
202 Carnegie Center, Suite 301
Princeton NEW JERSEY 10169 US
CEO: Claus Juan Moller San Pedro
Employees: 104
Phone: 16468858505
Y-MABS THERAPEUTICS INC / YMAB FAQ
What does YMAB do?
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
What is the stock price of Y-MABS THERAPEUTICS INC today?
The current stock price of YMAB is 8.61 USD. The price increased by 0.23% in the last trading session.
What is the dividend status of Y-MABS THERAPEUTICS INC?
YMAB does not pay a dividend.
What is the ChartMill technical and fundamental rating of YMAB stock?
YMAB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of Y-MABS THERAPEUTICS INC (YMAB)?
Y-MABS THERAPEUTICS INC (YMAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
What is the expected growth for YMAB stock?
The Revenue of Y-MABS THERAPEUTICS INC (YMAB) is expected to decline by -5.98% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.